FCGR2A promoter methylation and risks for intravenous immunoglobulin treatment responses in kawasaki disease

Ho Chang Kuo, Yu Wen Hsu, Mei Shin Wu, Peng Yeong Woon, Henry Sung Ching Wong, Li Jen Tsai, Ruo Kai Lin, Sukhontip Klahan, Kai Sheng Hsieh, Wei Chiao Chang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Kawasaki disease (KD) is characterized by pediatric systemic vasculitis of an unknown cause. The low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A) gene was reported to be involved in the susceptibility of KD. DNA methylation is one of the epigenetic mechanisms that control gene expression; thus, we hypothesized that methylation status of CpG islands in FCGR2A promoter associates with the susceptibility and therapeutic outcomes of Kawasaki disease. In this study, 36 KD patients and 24 healthy subjects from out-patient clinic were recruited. Eleven potential methylation sites within the targeted promoter region of FCGR2A were selected for investigation. We marked the eleven methylation sites from A to K. Our results indicated that methylation at the CpG sites G, H, and J associated with the risk of KD. CpG sites B, C, E, F, H, J, and K were found to associate with the outcomes of IVIG treatment. In addition, CpG sites G, J, and K were predicted as transcription factors binding sites for NF-kB, Myc-Max, and SP2, respectively. Our study reported a significant association among the promoter methylation of FCGR2A, susceptibility of KD, and the therapeutic outcomes of IVIG treatment. The methylation levels of CpG sites of FCGR2A gene promoter should be an important marker for optimizing IVIG therapy.

Original languageEnglish
Article number564625
JournalMediators of Inflammation
Volume2015
DOIs
Publication statusPublished - 2015

Fingerprint

Mucocutaneous Lymph Node Syndrome
Intravenous Immunoglobulins
Methylation
Therapeutics
IgG Receptors
Systemic Vasculitis
CpG Islands
NF-kappa B
DNA Methylation
Genetic Promoter Regions
Epigenomics
Genes
Immunoglobulins
Healthy Volunteers
Transcription Factors
Outpatients
Binding Sites
Pediatrics
Gene Expression

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

FCGR2A promoter methylation and risks for intravenous immunoglobulin treatment responses in kawasaki disease. / Kuo, Ho Chang; Hsu, Yu Wen; Wu, Mei Shin; Woon, Peng Yeong; Wong, Henry Sung Ching; Tsai, Li Jen; Lin, Ruo Kai; Klahan, Sukhontip; Hsieh, Kai Sheng; Chang, Wei Chiao.

In: Mediators of Inflammation, Vol. 2015, 564625, 2015.

Research output: Contribution to journalArticle

Kuo, Ho Chang ; Hsu, Yu Wen ; Wu, Mei Shin ; Woon, Peng Yeong ; Wong, Henry Sung Ching ; Tsai, Li Jen ; Lin, Ruo Kai ; Klahan, Sukhontip ; Hsieh, Kai Sheng ; Chang, Wei Chiao. / FCGR2A promoter methylation and risks for intravenous immunoglobulin treatment responses in kawasaki disease. In: Mediators of Inflammation. 2015 ; Vol. 2015.
@article{2964c346bba74a468c2f50e3c451b008,
title = "FCGR2A promoter methylation and risks for intravenous immunoglobulin treatment responses in kawasaki disease",
abstract = "Kawasaki disease (KD) is characterized by pediatric systemic vasculitis of an unknown cause. The low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A) gene was reported to be involved in the susceptibility of KD. DNA methylation is one of the epigenetic mechanisms that control gene expression; thus, we hypothesized that methylation status of CpG islands in FCGR2A promoter associates with the susceptibility and therapeutic outcomes of Kawasaki disease. In this study, 36 KD patients and 24 healthy subjects from out-patient clinic were recruited. Eleven potential methylation sites within the targeted promoter region of FCGR2A were selected for investigation. We marked the eleven methylation sites from A to K. Our results indicated that methylation at the CpG sites G, H, and J associated with the risk of KD. CpG sites B, C, E, F, H, J, and K were found to associate with the outcomes of IVIG treatment. In addition, CpG sites G, J, and K were predicted as transcription factors binding sites for NF-kB, Myc-Max, and SP2, respectively. Our study reported a significant association among the promoter methylation of FCGR2A, susceptibility of KD, and the therapeutic outcomes of IVIG treatment. The methylation levels of CpG sites of FCGR2A gene promoter should be an important marker for optimizing IVIG therapy.",
author = "Kuo, {Ho Chang} and Hsu, {Yu Wen} and Wu, {Mei Shin} and Woon, {Peng Yeong} and Wong, {Henry Sung Ching} and Tsai, {Li Jen} and Lin, {Ruo Kai} and Sukhontip Klahan and Hsieh, {Kai Sheng} and Chang, {Wei Chiao}",
year = "2015",
doi = "10.1155/2015/564625",
language = "English",
volume = "2015",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - FCGR2A promoter methylation and risks for intravenous immunoglobulin treatment responses in kawasaki disease

AU - Kuo, Ho Chang

AU - Hsu, Yu Wen

AU - Wu, Mei Shin

AU - Woon, Peng Yeong

AU - Wong, Henry Sung Ching

AU - Tsai, Li Jen

AU - Lin, Ruo Kai

AU - Klahan, Sukhontip

AU - Hsieh, Kai Sheng

AU - Chang, Wei Chiao

PY - 2015

Y1 - 2015

N2 - Kawasaki disease (KD) is characterized by pediatric systemic vasculitis of an unknown cause. The low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A) gene was reported to be involved in the susceptibility of KD. DNA methylation is one of the epigenetic mechanisms that control gene expression; thus, we hypothesized that methylation status of CpG islands in FCGR2A promoter associates with the susceptibility and therapeutic outcomes of Kawasaki disease. In this study, 36 KD patients and 24 healthy subjects from out-patient clinic were recruited. Eleven potential methylation sites within the targeted promoter region of FCGR2A were selected for investigation. We marked the eleven methylation sites from A to K. Our results indicated that methylation at the CpG sites G, H, and J associated with the risk of KD. CpG sites B, C, E, F, H, J, and K were found to associate with the outcomes of IVIG treatment. In addition, CpG sites G, J, and K were predicted as transcription factors binding sites for NF-kB, Myc-Max, and SP2, respectively. Our study reported a significant association among the promoter methylation of FCGR2A, susceptibility of KD, and the therapeutic outcomes of IVIG treatment. The methylation levels of CpG sites of FCGR2A gene promoter should be an important marker for optimizing IVIG therapy.

AB - Kawasaki disease (KD) is characterized by pediatric systemic vasculitis of an unknown cause. The low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A) gene was reported to be involved in the susceptibility of KD. DNA methylation is one of the epigenetic mechanisms that control gene expression; thus, we hypothesized that methylation status of CpG islands in FCGR2A promoter associates with the susceptibility and therapeutic outcomes of Kawasaki disease. In this study, 36 KD patients and 24 healthy subjects from out-patient clinic were recruited. Eleven potential methylation sites within the targeted promoter region of FCGR2A were selected for investigation. We marked the eleven methylation sites from A to K. Our results indicated that methylation at the CpG sites G, H, and J associated with the risk of KD. CpG sites B, C, E, F, H, J, and K were found to associate with the outcomes of IVIG treatment. In addition, CpG sites G, J, and K were predicted as transcription factors binding sites for NF-kB, Myc-Max, and SP2, respectively. Our study reported a significant association among the promoter methylation of FCGR2A, susceptibility of KD, and the therapeutic outcomes of IVIG treatment. The methylation levels of CpG sites of FCGR2A gene promoter should be an important marker for optimizing IVIG therapy.

UR - http://www.scopus.com/inward/record.url?scp=84930965711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930965711&partnerID=8YFLogxK

U2 - 10.1155/2015/564625

DO - 10.1155/2015/564625

M3 - Article

C2 - 26089602

AN - SCOPUS:84930965711

VL - 2015

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 564625

ER -